MARKET

MLND

MLND

Millendo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.70
+0.42
+6.69%
Closed 16:00 09/16 EDT
OPEN
6.41
PREV CLOSE
6.28
HIGH
6.87
LOW
6.35
VOLUME
31.64K
TURNOVER
--
52 WEEK HIGH
17.34
52 WEEK LOW
4.560
MARKET CAP
89.86M
P/E (TTM)
-0.5249
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MLND and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MLND News

  • Jefferies Assumes Millendo Therapeutics at Buy, Announces $22 Price Target
  • Benzinga.22h ago
  • Millendo Therapeutics to Participate in September Investor Conferences
  • Business Wire.08/29 12:30
  • Millendo Therapeutics Appoints Tamara Joseph as General Counsel and Ryan Zeidan as Chief Development Officer
  • Business Wire.08/20 13:30
  • Millendo Therapeutics (MLND) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
  • Seeking Alpha - Article.08/15 18:20

More

Industry

Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About MLND

Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.
More

Webull offers Millendo Therapeutics Inc (MLND) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.